UN agency supports patient radiation tracking program
The International Atomic Energy Agency is backing plans to keep track of how much medical radiation patients are exposed to over time by issuing smart cards and modifying electronic medical records.
The International Atomic Energy Agency is backing plans to keep track of how much medical radiation patients are exposed to over time by issuing smart cards and modifying electronic medical records.
The IAEA announced April 29 an initiative that relies on imaging equipment vendors and IT experts to develop a long-term radiation exposure record for patients available whenever and wherever they go for a scan. All modalities would have to display the dose delivered in a standardized format, while hospitals and clinics would also need an EMR system that can store individual dose data and produce a running total of lifetime x-ray exposure. Tangible results from the project, which is being funded jointly by the IAEA and the U.S. Nuclear Regulatory Commission, can be expected within the next three to five years.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
